摘要
目的探讨MIS18BP1在膀胱癌中的表达、与临床病理参数相关性及临床意义。方法TCGA、GEO数据库分析MIS18BP1在肿瘤和对照组中mRNA表达并经qRT-PCR验证;UALCAN在线数据库分析MIS18BP1表达及与临床病理参数、免疫细胞浸润程度相关性;免疫组织化学分析MIS18BP1在膀胱癌中的表达及与临床病理特征的关系;ROC曲线评价MIS18BP1 mRNA对膀胱癌的诊断价值。结果生物信息学分析及qRT-PCR结果显示,与对照组相比较,MIS18BP1 mRNA在膀胱癌中表达增加(P<0.05);免疫组织化学结果表明膀胱癌MIS18BP1蛋白阳性率显著增高(P<0.05),且与肿瘤临床分期、浸润深度及淋巴结转移相关(P<0.05);免疫浸润分析显示MIS18BP1与膀胱癌中免疫细胞浸润相关。结论MIS18BP1基因和蛋白在膀胱癌中表达水平增高,可能通过影响免疫细胞浸润调控膀胱癌的发生发展。
Objective To explore the expression,correlation with clinicopathologic parameters,and clinical significance of MIS18 binding protein 1(MIS18BP1)in bladder cancer:Methods TCGA and GEO data-bases were used to analyze the mRNA expression of MIS18BP1 in tumors and controls,and the results were verified via qRT-PCR.UALCAN online database was utilized in the analysis of the expression of MIS18BP1 and its correlation with clinicopathological parameters and the degree of immune cell infiltration.Immun-ohistochemistry was employed to analyze the expression of MIS18BP1 in bladder cancer and its relationship with clinicopathological features.The ROC curve was applied to evaluate the diagnostic value of MIS18BP1 mRNA in bladder cancer.Results Bioinformatics analysis and qRT-PCR results revealed the increased expression of MIS18BP1 mRNA in bladder cancer compared with that in the control group(P<0.05).Immunohistochemistry unveiled the significantly high positive rate of MIS18BP1 protein in bladder cancer(P<0.05)and its correlation with the clinical stage of tumors,depth of invasion,and lymph node metastasis(P<0.05).The immune infiltration analysis showed the association of MIS18BP1 with immune cell infil-tration in bladder cancer,Conclusion The increased expression level of MIS18BP1 gene and protein in bladder cancer may regulate the development of bladder cancer by influencing immune cell infiltration.
作者
曹文静
汪煜琳
翟雨晴
张宗亮
原江水
宋卫青
CAO Wenjing;WANG Yulin;ZHAI Yuqing;ZHANG Zongliang;YUAN Jiangshui;SONG Weiqing(Department of Medicine,Qingdao University,Qingdao 266011,China;Department of Laboratory Medicine,Qingdao Municipal Hospital,Qingdao 266011,China;Graduate School of Dalian Medical University,Dalian 116041,China;Department of Urology,Affiliated Hospital of Qingdao University,Qingdao 266011,China)
出处
《肿瘤防治研究》
CAS
2024年第3期163-168,共6页
Cancer Research on Prevention and Treatment
基金
国家自然科学基金(31971191)。